Jaguar Health Registers 40.8M Shares for C/M Capital ELOC Resale — Potential 89% Dilution Overhang
JAGX is trading near its 52-week low of $1.94 (8.2% above the low).
Summary
Jaguar Health filed an S-1 to register 40.8 million shares for resale by C/M Capital under a $40 million equity line of credit. If fully drawn, the shares would represent over 89% of current outstanding shares, creating a massive dilution overhang. The filing confirms shares will be sold at a minimum 5% discount to market.
Key Events · Financing and Capital Events · JAGX
-
ELOC Registration Filed
Jaguar filed an S-1 to register 40.8 million shares for resale by C/M Capital under the $40 million equity line of credit. The shares represent over 89% of the 4.9 million shares currently outstanding, creating a massive potential dilution overhang.
-
Pricing Mechanism Confirmed
The filing confirms shares will be sold to C/M Capital at a minimum 5% discount to market. The VWAP Purchase Price is set at 95% of the lowest of the VWAP, the 5-day low, or the closing price, ensuring C/M Capital can acquire shares below market and potentially resell immediately.
-
Commitment Shares Issued
As consideration for the ELOC, Jaguar will issue $800,000 worth of common stock to C/M Capital upon SEC effectiveness of the registration statement, valued at the VWAP Purchase Price, adding immediate dilution.
-
Financing Now Operational Pending SEC Clearance
The S-1 filing is a required step to activate the ELOC. Once the SEC declares the registration effective, Jaguar can begin drawing funds at its discretion, subject to a $1.10 floor price and other conditions.
Analysis · JAGX · Life Sciences
Jaguar Health filed the S-1 registration statement to enable the $40 million equity line of credit (ELOC) with C/M Capital, a financing approved by shareholders on June 8. The registration covers up to 40.8 million shares for resale, which would represent over 89% of the current outstanding shares if fully issued. The filing confirms the ELOC pricing mechanism: shares will be sold to C/M Capital at a minimum 5% discount to market, with the VWAP Purchase Price set at 95% of the lowest of the VWAP, the 5-day low, or the closing price. This structure creates a significant overhang and potential for substantial dilution, especially given Jaguar's micro-cap status (~$9.5M market cap) and history of heavy dilution. The ELOC is now one step closer to being usable, with the registration statement needing SEC effectiveness before any sales can occur.
At the time of this filing, JAGX was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $1.94 to $92.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.